Page 20 - Pharma Companies
Moderna's Covid-19 vaccine may come to India through govt route
Players like Indian Immunologicals willing to partner US firm to manufacture here
 "Moderna's Covid-19 vaccine may come to India through govt route")
Moderna's Covid vaccine 94.5% effective, edges over Pfizer on storage
Its vaccine's temperature requirements give it an edge over Pfizer's for distribution in India
Moderna Inc on track to report coronavirus vaccine data in November
Hopes of the world soon getting an effective vaccine were raised on Monday
 "Moderna Inc on track to report coronavirus vaccine data in November")
EU to buy up to 300 million doses of Pfizer-BioNTech Covid-19 vaccine
The European Commission will sign a deal to secure up to 300 million doses of the experimental coronavirus vaccine developed by BioNTech and Pfizer
 "EU to buy up to 300 million doses of Pfizer-BioNTech Covid-19 vaccine")
Gland Pharma IPO: Expensive at a price tag of 30x the FY20 earnings
While prospects remain strong led by niche products and a differentiated business model, relatively rich valuations leave limited scope for upside in near-term
 "Gland Pharma IPO: Expensive at a price tag of 30x the FY20 earnings")
AstraZeneca Pharma India Q2 net profit up 83% at Rs 26.33 crore
Drug firm AstraZeneca Pharma India on Thursday reported an 83.48 per cent rise in its net profit at Rs 26.33 crore for the quarter ended September 2020. The company had posted a net profit of Rs 14.41 crore for the corresponding period of the previous fiscal, it said in a filing to the BSE. Revenue from operations stood at Rs 209.47 crore for the quarter under consideration. It was Rs 208.48 crore for the same period a year ago, it added. Shares of AstraZeneca Pharma India closed at Rs4,295.80per scrip on the BSE, up 0.40 per cent from their previous close.
 "AstraZeneca Pharma India Q2 net profit up 83% at Rs 26.33 crore")
Street concerns ease as Sun Pharma's specialty segment delivers in Q2
Upsides in the stock will depend on sustaining specialty and India sales growth
 "Street concerns ease as Sun Pharma's specialty segment delivers in Q2")
Strides Pharma to set up 800-mn capacity vaccine suite in Bengaluru
In talks with global players seeking manufacturing opportunity for potential Covid-19 vaccine
 "Strides Pharma to set up 800-mn capacity vaccine suite in Bengaluru")
Novavax delays US trial of Covid-19 vaccine candidate to November
The US-based drug developer said data from a separate phase 3 trial being conducted in Britain was expected by the first quarter of 2021
 "Novavax delays US trial of Covid-19 vaccine candidate to November")
Aurobindo Pharma to sell US-based Natrol for about Rs 4,048 crore
Aurobindo's stock reacted positively to the news, going up in morning trade but later settled flat at Rs 784.65 on the BSE
 "Aurobindo Pharma to sell US-based Natrol for about Rs 4,048 crore")
Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity
The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.
 "Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity")
Strong prospects of Biologics business keep Street positive on Biocon
Even though Q2 performance missed estimates, analysts expect a stronger second half
 "Strong prospects of Biologics business keep Street positive on Biocon")
Oxford Covid-19 vaccine doing everything expected', independent study finds
The experts say that the novel analysis provides even greater clarity and detail about how the vaccine successfully provokes a strong immune response.
 "Oxford Covid-19 vaccine doing everything expected', independent study finds")
Roche Holding sales disappoint as drugs decline eclipses Covid-19 tests
The Swiss drugmaker's revenue rose 1% to 14.7 billion francs ($16.1 billion), the company said
 "Roche Holding sales disappoint as drugs decline eclipses Covid-19 tests")
3 firms get clinical trial approval for alternative Covid-19 drugs
The drug 2-DG is not yet an approved drug, but there have been multiple studies across the globe for treatment of cancers
Smaller pharma firms post faster domestic sales growth in September
Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth
 "Smaller pharma firms post faster domestic sales growth in September")
PE/VC investments in pharma companies grow 3.5X in 2020, cross $1 bn mark
The reputation and relationships have helped pharma industry raise huge amounts of PE capital in 2020.
 "PE/VC investments in pharma companies grow 3.5X in 2020, cross $1 bn mark")
Patented molecules clock a high growth rate in Indian cardiovascular market
In January 2020, the Delhi High Court granted an injunction restraining domestic companies such as Cipla, Torrent, Emcure, and Alkem from launching their brands
 "Patented molecules clock a high growth rate in Indian cardiovascular market")
Revised, more industry-friendly PLI scheme for bulk drugs on the cards
Industry says move will mean lower spends and reduced dependence on China
 "Revised, more industry-friendly PLI scheme for bulk drugs on the cards")
Credit metrics of leading pharma companies to remain stable: ICRA
The global demand scenario for Indian pharmaceutical industry is largely expected to remain stable due to inelastic nature of prescription drugs, investment information agency ICRA has said.
